Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
SRDX's Cash-to-Debt is ranked higher than
97% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. SRDX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
SRDX' s Cash-to-Debt Range Over the Past 10 Years
Min: 50.6  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.83
SRDX's Equity-to-Asset is ranked higher than
81% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. SRDX: 0.83 )
Ranked among companies with meaningful Equity-to-Asset only.
SRDX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.74  Med: 0.92 Max: 0.96
Current: 0.83
0.74
0.96
Interest Coverage No Debt
SRDX's Interest Coverage is ranked higher than
97% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.16 vs. SRDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SRDX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 12.09
Beneish M-Score: -2.60
WACC vs ROIC
5.50%
9.66%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 15.13
SRDX's Operating Margin % is ranked higher than
92% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. SRDX: 15.13 )
Ranked among companies with meaningful Operating Margin % only.
SRDX' s Operating Margin % Range Over the Past 10 Years
Min: -20.11  Med: 30.13 Max: 47.31
Current: 15.13
-20.11
47.31
Net Margin % 8.57
SRDX's Net Margin % is ranked higher than
86% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. SRDX: 8.57 )
Ranked among companies with meaningful Net Margin % only.
SRDX' s Net Margin % Range Over the Past 10 Years
Min: -35.08  Med: 17.25 Max: 30.9
Current: 8.57
-35.08
30.9
ROE % 5.70
SRDX's ROE % is ranked higher than
63% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. SRDX: 5.70 )
Ranked among companies with meaningful ROE % only.
SRDX' s ROE % Range Over the Past 10 Years
Min: -12.91  Med: 10.43 Max: 23.9
Current: 5.7
-12.91
23.9
ROA % 4.68
SRDX's ROA % is ranked higher than
79% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. SRDX: 4.68 )
Ranked among companies with meaningful ROA % only.
SRDX' s ROA % Range Over the Past 10 Years
Min: -11.85  Med: 8.38 Max: 19.94
Current: 4.68
-11.85
19.94
ROC (Joel Greenblatt) % 44.71
SRDX's ROC (Joel Greenblatt) % is ranked higher than
88% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. SRDX: 44.71 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SRDX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -18.72  Med: 85.11 Max: 110.87
Current: 44.71
-18.72
110.87
3-Year Revenue Growth Rate 12.30
SRDX's 3-Year Revenue Growth Rate is ranked higher than
71% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. SRDX: 12.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SRDX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -24.6  Med: 15.45 Max: 57.9
Current: 12.3
-24.6
57.9
3-Year EBITDA Growth Rate 3.70
SRDX's 3-Year EBITDA Growth Rate is ranked lower than
53% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. SRDX: 3.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SRDX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -32.7  Med: 14.05 Max: 90.6
Current: 3.7
-32.7
90.6
3-Year EPS without NRI Growth Rate -8.40
SRDX's 3-Year EPS without NRI Growth Rate is ranked lower than
61% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. SRDX: -8.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SRDX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -35.4  Med: 11.8 Max: 48.3
Current: -8.4
-35.4
48.3
GuruFocus has detected 6 Warning Signs with Surmodics Inc $SRDX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SRDX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-16 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

SRDX Guru Trades in Q3 2016

Jim Simons 860,138 sh (+1.13%)
Mario Gabelli 106,048 sh (-1.39%)
Mairs and Power 10,338 sh (-11.64%)
Paul Tudor Jones 9,647 sh (-20.97%)
Chuck Royce 328,092 sh (-34.72%)
» More
Q4 2016

SRDX Guru Trades in Q4 2016

Jim Simons 964,038 sh (+12.08%)
Chuck Royce 328,092 sh (unchged)
Mairs and Power Sold Out
Mario Gabelli 105,648 sh (-0.38%)
Paul Tudor Jones 8,878 sh (-7.97%)
» More
Q1 2017

SRDX Guru Trades in Q1 2017

Chuck Royce 368,092 sh (+12.19%)
Jim Simons 1,002,721 sh (+4.01%)
Mario Gabelli 105,648 sh (unchged)
Paul Tudor Jones 8,502 sh (-4.24%)
» More
Q2 2017

SRDX Guru Trades in Q2 2017

Chuck Royce 372,792 sh (+1.28%)
Jim Simons 1,004,338 sh (+0.16%)
Mario Gabelli 105,648 sh (unchged)
Paul Tudor Jones 7,825 sh (-7.96%)
» More
» Details

Insider Trades

Latest Guru Trades with SRDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2016-12-31 Reduce -0.38%$23.75 - $30.42 $ 30.0514%105,648
Mario Gabelli 2016-09-30 Reduce -1.39%$23.8 - $30.09 $ 30.059%106,048
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:AMEX:SENS, NYSE:NVTA, NYSE:ARA, NYSE:ENZ, NAS:ONVO, NAS:RDNT, NAS:FLDM, NAS:MGEN, LSE:MXCR, NAS:CTSO, NAS:AIQ, NAS:TTOO, NAS:VIVO, XKRX:950140, NAS:PACB, NAS:PMD, AMEX:PTN, NAS:LNTH, NAS:FLGT, NAS:VRML » details
Traded in other countries:SU6.Germany,
Headquarter Location:USA
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry.

Surmodics Inc was organized as a Minnesota corporation in June 1979. The Company is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. Its business units are organized and managed in two reportable segments, Medical Device and In Vitro Diagnostics. The core offerings in its Medical Device business unit include surface modification coating technologies that impart lubricity, prohealing or biocompatibility characteristics, or drug delivery capabilities. It manufactures or sells components for in vitro diagnostic immunoassay and molecular tests and it manufactures and sells surface coatings to the diagnostic, biomedical research, and life science markets. The In Vitro Diagnostics products include Protein Stabilizers, Substrates, Recombinant Human Antigens, and Surface Coatings for Molecular Diagnostic Applications.

Ratios

vs
industry
vs
history
PE Ratio 65.34
SRDX's PE Ratio is ranked lower than
54% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.78 vs. SRDX: 65.34 )
Ranked among companies with meaningful PE Ratio only.
SRDX' s PE Ratio Range Over the Past 10 Years
Min: 8.52  Med: 29.34 Max: 584.75
Current: 65.34
8.52
584.75
PE Ratio without NRI 65.34
SRDX's PE Ratio without NRI is ranked lower than
52% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 38.46 vs. SRDX: 65.34 )
Ranked among companies with meaningful PE Ratio without NRI only.
SRDX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.52  Med: 28.95 Max: 584.75
Current: 65.34
8.52
584.75
Price-to-Owner-Earnings 56.26
SRDX's Price-to-Owner-Earnings is ranked higher than
53% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.54 vs. SRDX: 56.26 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SRDX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.81  Med: 40.22 Max: 281.56
Current: 56.26
13.81
281.56
PB Ratio 3.61
SRDX's PB Ratio is ranked higher than
57% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. SRDX: 3.61 )
Ranked among companies with meaningful PB Ratio only.
SRDX' s PB Ratio Range Over the Past 10 Years
Min: 0.98  Med: 3.02 Max: 7.42
Current: 3.61
0.98
7.42
PS Ratio 5.66
SRDX's PS Ratio is ranked lower than
60% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. SRDX: 5.66 )
Ranked among companies with meaningful PS Ratio only.
SRDX' s PS Ratio Range Over the Past 10 Years
Min: 2.17  Med: 5.14 Max: 13.77
Current: 5.66
2.17
13.77
Price-to-Free-Cash-Flow 66.18
SRDX's Price-to-Free-Cash-Flow is ranked lower than
67% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. SRDX: 66.18 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SRDX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.26  Med: 20.82 Max: 503.11
Current: 66.18
7.26
503.11
Price-to-Operating-Cash-Flow 28.18
SRDX's Price-to-Operating-Cash-Flow is ranked higher than
54% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.14 vs. SRDX: 28.18 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SRDX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.99  Med: 16.02 Max: 30.15
Current: 28.18
5.99
30.15
EV-to-EBIT 32.48
SRDX's EV-to-EBIT is ranked higher than
63% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SRDX: 32.48 )
Ranked among companies with meaningful EV-to-EBIT only.
SRDX' s EV-to-EBIT Range Over the Past 10 Years
Min: -37.7  Med: 15.65 Max: 103.8
Current: 32.48
-37.7
103.8
EV-to-EBITDA 21.94
SRDX's EV-to-EBITDA is ranked higher than
63% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. SRDX: 21.94 )
Ranked among companies with meaningful EV-to-EBITDA only.
SRDX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -167.5  Med: 13.1 Max: 66.8
Current: 21.94
-167.5
66.8
EV-to-Revenue 4.95
SRDX's EV-to-Revenue is ranked lower than
55% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. SRDX: 4.95 )
Ranked among companies with meaningful EV-to-Revenue only.
SRDX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.9  Med: 4.4 Max: 12.9
Current: 4.95
1.9
12.9
PEG Ratio 5.95
SRDX's PEG Ratio is ranked lower than
56% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.20 vs. SRDX: 5.95 )
Ranked among companies with meaningful PEG Ratio only.
SRDX' s PEG Ratio Range Over the Past 10 Years
Min: 1.32  Med: 3.38 Max: 10.9
Current: 5.95
1.32
10.9
Shiller PE Ratio 66.06
SRDX's Shiller PE Ratio is ranked lower than
71% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 47.44 vs. SRDX: 66.06 )
Ranked among companies with meaningful Shiller PE Ratio only.
SRDX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.08  Med: 43.79 Max: 132.12
Current: 66.06
17.08
132.12
Current Ratio 7.64
SRDX's Current Ratio is ranked higher than
89% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. SRDX: 7.64 )
Ranked among companies with meaningful Current Ratio only.
SRDX' s Current Ratio Range Over the Past 10 Years
Min: 1.57  Med: 5.96 Max: 18.27
Current: 7.64
1.57
18.27
Quick Ratio 7.18
SRDX's Quick Ratio is ranked higher than
88% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. SRDX: 7.18 )
Ranked among companies with meaningful Quick Ratio only.
SRDX' s Quick Ratio Range Over the Past 10 Years
Min: 1.49  Med: 5.43 Max: 18
Current: 7.18
1.49
18
Days Inventory 115.06
SRDX's Days Inventory is ranked lower than
63% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.72 vs. SRDX: 115.06 )
Ranked among companies with meaningful Days Inventory only.
SRDX' s Days Inventory Range Over the Past 10 Years
Min: 33.96  Med: 123.11 Max: 168.39
Current: 115.06
33.96
168.39
Days Sales Outstanding 35.85
SRDX's Days Sales Outstanding is ranked higher than
84% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. SRDX: 35.85 )
Ranked among companies with meaningful Days Sales Outstanding only.
SRDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.19  Med: 35.38 Max: 80.51
Current: 35.85
30.19
80.51
Days Payable 63.91
SRDX's Days Payable is ranked higher than
57% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. SRDX: 63.91 )
Ranked among companies with meaningful Days Payable only.
SRDX' s Days Payable Range Over the Past 10 Years
Min: 33.07  Med: 57.73 Max: 166.09
Current: 63.91
33.07
166.09

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.70
SRDX's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. SRDX: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SRDX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5.1  Med: 0.9 Max: 8.1
Current: 1.7
-5.1
8.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 18.66
SRDX's Price-to-Net-Cash is ranked lower than
57% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.16 vs. SRDX: 18.66 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SRDX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.9  Med: 22.36 Max: 700
Current: 18.66
3.9
700
Price-to-Net-Current-Asset-Value 11.21
SRDX's Price-to-Net-Current-Asset-Value is ranked higher than
50% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.24 vs. SRDX: 11.21 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SRDX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.27  Med: 15.98 Max: 160.14
Current: 11.21
3.27
160.14
Price-to-Tangible-Book 6.42
SRDX's Price-to-Tangible-Book is ranked lower than
54% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.17 vs. SRDX: 6.42 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SRDX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.26  Med: 4.62 Max: 18.49
Current: 6.42
1.26
18.49
Price-to-Intrinsic-Value-Projected-FCF 1.41
SRDX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
83% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. SRDX: 1.41 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SRDX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.4 Max: 4.58
Current: 1.41
0.52
4.58
Price-to-Median-PS-Value 1.10
SRDX's Price-to-Median-PS-Value is ranked higher than
58% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. SRDX: 1.10 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SRDX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48  Med: 1.57 Max: 9.44
Current: 1.1
0.48
9.44
Price-to-Peter-Lynch-Fair-Value 11.60
SRDX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
80% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. SRDX: 11.60 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
SRDX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.47  Med: 1.86 Max: 31.8
Current: 11.6
0.47
31.8
Price-to-Graham-Number 4.32
SRDX's Price-to-Graham-Number is ranked higher than
55% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.54 vs. SRDX: 4.32 )
Ranked among companies with meaningful Price-to-Graham-Number only.
SRDX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.91  Med: 2.8 Max: 13.55
Current: 4.32
0.91
13.55
Earnings Yield (Greenblatt) % 3.05
SRDX's Earnings Yield (Greenblatt) % is ranked higher than
81% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. SRDX: 3.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SRDX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -10.7  Med: 5.9 Max: 22
Current: 3.05
-10.7
22
Forward Rate of Return (Yacktman) % 9.36
SRDX's Forward Rate of Return (Yacktman) % is ranked higher than
65% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.57 vs. SRDX: 9.36 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
SRDX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2  Med: 5.1 Max: 36.4
Current: 9.36
2
36.4

More Statistics

Revenue (TTM) (Mil) $71.21
EPS (TTM) $ 0.46
Beta0.55
Short Percentage of Float4.07%
52-Week Range $21.90 - 30.75
Shares Outstanding (Mil)13.11

Analyst Estimate

Sep17 Sep18 Sep19
Revenue (Mil $) 70 73 79
EPS ($) 0.28 -0.04 -0.09
EPS without NRI ($) 0.28 -0.04 -0.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.00%
Dividends per Share ($)
» More Articles for SRDX

Headlines

Articles On GuruFocus.com
5 Best Stocks for Value Investors This Week Feb 19 2017 
SurModics Inc. Reports Operating Results (10-Q) Aug 06 2010 
SurModics Inc. Reports Operating Results (10-Q) May 07 2010 
SurModics Inc. Reports Operating Results (10-Q) Feb 05 2010 
SurModics Inc. Reports Operating Results (10-K) Dec 11 2009 
SurModics Inc. (SRDX) Senior VP & CFO Philip D Ankeny sells 5,000 Shares Oct 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Aug 07 2009 
SurModics Inc. Reports Operating Results (10-Q) May 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
Surmodics Receives FDA's Approval for PTA Balloon Catheter Sep 19 2017
Edited Transcript of SRDX earnings conference call or presentation 3-Aug-17 12:30pm GMT Sep 18 2017
Surmodics Announces Global Approvals of .014" Low-Profile PTA Balloon Dilation Catheter Sep 18 2017
Surmodics Presents Encouraging SurVeil DCB Data at VIVA Meet Sep 15 2017
Six-Month Data from the Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented at... Sep 13 2017
SurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : September 5, 2017 Sep 05 2017
SurModics, Inc. – Value Analysis (NASDAQ:SRDX) : August 15, 2017 Aug 15 2017
Surmodics (SRDX) Beats Earnings & Revenue Estimates in Q3 Aug 07 2017
SurModics posts 3Q profit Aug 03 2017
Surmodics Reports Third Quarter Fiscal 2017 Results and Updates Fiscal 2017 Guidance Aug 03 2017
SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : August 2, 2017 Aug 02 2017
Surmodics Receives IDE Approval to Initiate Pivotal Trial of the SurVeil™ Drug-Coated Balloon Jul 26 2017
Surmodics to Webcast Third Quarter 2017 Earnings Conference Call on August 3 Jul 25 2017
SurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : May 29, 2017 May 29 2017
Surmodics to Present at Upcoming Investor Conferences May 22 2017
ETFs with exposure to SurModics, Inc. : May 5, 2017 May 05 2017
SurModics, Inc. :SRDX-US: Earnings Analysis: Q2, 2017 By the Numbers : May 3, 2017 May 03 2017
Edited Transcript of SRDX earnings conference call or presentation 27-Apr-17 12:30pm GMT May 01 2017
SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : April 28, 2017 Apr 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}